The Latest: WHO endorses antibody treatment for some people

LONDON — The World Health Organization is recommending a pricey antibody treatment for certain coronavirus patients in the latest update to its guidelines for treating people with COVID-19.

The new guidelines, published Friday in the journal BMJ, say the two antibodies - casirivimab and imdevimab = made by Regeneron should be given to people infected with COVID-19 who are at highest risk of hospitalization and to people whose own immune systems have not mounted a response.

The U.N. health agency said the new advice was based on evidence from experimental trials, including a British-run study that is the world’s largest for testing potential COVID-19 treatments.

In the U.S., the Regeneron treatment is mostly recommended for people with mild to moderate COVID-19, to prevent them from needing hospitalization.

Activists worried that the cost of the treatment - more than $2,000 in the U.S. - means it will mostly be unavailable to people in poorer countries. Doctors Without Borders called for Regeneron to ensure the antibody drugs are accessible to needy patients and for the company to license any proprietary rights and share technological know-how for how to make them.

___

MORE ON THE PANDEMIC:

— CDC endorses COVID booster shots for millions of older Americans

— ″Vaccine apartheid’: Africans tells UN they need vaccines

— More rental aid is reaching U.S. tenants to stave off eviction

— Polish protesters warn that health care crisis is looming

___

See all of AP's pandemic coverage at https://apnews.com/hub/coronavirus-pandemic

___

HERE’S WHAT ELSE IS HAPPENING:

SINGAPORE — Singapore’s Ministry of Health is tightening...